GPBAR1 and metabolic disease: BA metabolic disorders lead to cholestasis and intestinal inflammation, reduce the expression and receptor activity of FXR/TGR5, reduce renal protective function, increase proteinuria, and promote podocyte injury, lipid accumulation, and fibrosis.